FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 9, 2026
Design Therapeutics, Inc. (DSGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $69.8 million. Free cash flow was -$54.6 million. As of Sep 30, 2026 it held $208.6 million in cash and investments and $2.5 million in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-74.09M
-9.8% vs year-ago TTM
Operating cash flow (TTM)
$-59.30M
-13.5% vs year-ago TTM
Free cash flow (TTM)
$-59.37M
-13.3% vs year-ago TTM
EPS (TTM)
$-1.21
-1.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
61.67M
+8.6% vs prior year
Net cash
$206.09M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DSGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Carlsbad, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1807120
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Operating income | -$79.5M | -$62.4M | -$78.2M | -$67.6M | -$35.8M |
| Net income | -$69.8M | -$49.6M | -$66.9M | -$63.3M | -$35.5M |
| Diluted EPS | -$1.22 | -$0.88 | -$1.19 | -$1.14 | — |
| Operating cash flow | -$54.4M | -$43.1M | -$58.6M | -$51.3M | -$29.4M |
| Free cash flow | -$54.6M | -$43.4M | -$58.8M | -$52.2M | -$30.9M |
| Total assets | $226.2M | $252.1M | $289.6M | $341.1M | $390.6M |
| Total liabilities | $13.7M | $10.0M | $12.0M | $13.8M | $8.4M |
| Stockholders' equity | $212.5M | $242.1M | $277.7M | $327.3M | $382.1M |
| Cash and investments | $219.8M | $245.5M | $281.8M | $330.4M | $384.1M |
| Total debt | $1.5M | $2.3M | $3.0M | $3.7M | $3.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 3, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Other events
|
May 18, 2026 | May 18, 2026 |
All 268 Design Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.